The majority of the analysts thinks Gilead Sciences is currently underpriced. Currently the company is being followed by 13 analyst. The recommendations are: no sells, 9 times hold and 4 times buy. The average of the outstanding target prices for the stock is at 92,33 USD. This is approximately 25 percent more than the current price of 73,02 USD. The most recent recommendations for the biotech company are from Barclays , Morgan Stanley and Jefferies & Co..
Gilead Sciences 's market capitalization is based on the number of outstanding shares around 103,83 billion USD.
At 22.00 the stock trades 0,42 percent lower at 73,02 USD.
Analist.nl Nieuwsdienst: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.